
POXEL
A biopharmaceutical company developing innovative treatments for serious chronic metabolic diseases.
About
POXEL SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with a metabolic pathophysiology. Their primary areas of focus include metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases. The company announced a new Tranche D PDR subscription agreement with IPF Partners on March 25, 2026.
Show 6 more similar companies
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company focused on developing cancer immunotherapies.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Shares Biotechnology, Pharmaceuticals
Developing novel therapeutics to restore gut lymphatic function.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to POXEL?
People comparing tools land here. Get listed beside these.
All funding rounds
Key facts
- Website
- poxelpharma.com
- Headquarters
- Lyon, France
- Founded
- 2006
- Total funding
- $4M (Tranche D PDR Bond Issue)
- Business model
- B2B
Funding rounds
- $4M25 Mar 2026
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 25 Mar 2026 | Tranche D PDR Bond Issue | $4M |
Tech stack
Detected on poxelpharma.com, last scanned 3 Nov 2026. Run your own scan
- Frontend
- Bootstrap
- Hosting
- AWS
Benchmarking
See how your site ranks against 16,849 startups
POXEL sits in the 42nd percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingPOXEL has a Domain Rating of 34, the 42nd percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Below median
Check yoursAgent Readiness
Bottom 25%
Scan yoursSite Speed
Above median
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
POXEL scores 27. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentAI visibility
Get read by ChatGPT, Claude and Perplexity
List your startup, then track where you show up in AI answers.
AI reads of this profile
Last 14 days, from server logs
Get notified when POXEL changes
Used POXEL? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is POXEL growing?
Yes, fast. Our data shows it raised $3.8M in a Tranche D PDR Bond Issue in March 2026.
Who owns POXEL?
POXEL is privately held, owned by its founders and investors. Investors on record include IPF Partners. Exact stakes are not public.
Are there companies like POXEL?
Yes. We list 6 companies like POXEL, including Moderna, Juno Therapeutics and Kite Pharma.
Is POXEL trustworthy and reputable?
StartupHub's Data Trust & Reputation score for POXEL is 75 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has POXEL raised?
POXEL has raised a total of $4M in funding. The most recent round on record is Tranche D PDR Bond Issue.
SEC filings, insider activity, nonprofit links and pay benchmarks for POXEL:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch POXEL and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini


